LEO 138559
Sponsors
LEO Pharma
Conditions
Atopic Dermatitis
Phase 1
Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis
CompletedNCT03514511
Start: 2018-05-07End: 2021-03-02Updated: 2025-02-24
A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects
CompletedNCT05099133
Start: 2021-11-03End: 2022-06-28Updated: 2025-02-24
Phase 2
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
CompletedNCT04922021
Start: 2021-07-14End: 2022-09-26Updated: 2025-03-13
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
CompletedNCT05470114
Start: 2022-05-19End: 2023-10-09Updated: 2025-03-11
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
CompletedNCT05923099
Start: 2023-09-20End: 2025-04-09Updated: 2026-02-12